Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004026 · ClinicalTrials.gov registry record · Phase 2
CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy
A Phase 2 study, sponsored by CTI BioPharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00004026: Clinical Trial Phase 2 study, sponsored by CTI BioPharma.
NCT00004026 is a Phase 2 study that was terminated before completion, run by CTI BioPharma. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004026, a Phase 2 study, was terminated before completion, sponsored by CTI BioPharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. CT-2584 may stop the growth of prostate cancer by stopping blood flow to the tumor. PURPOSE: Randomized phase II trial to study the effectiveness of CT-2584 in treating patients who have metastatic prostate cancer that has not responded to previous therapy.
Interventions
- DRUG chemotherapy
- DRUG CT-2584
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 1998-12 |
| Est. Completion | 2005-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004026
The ClinicalTrials.gov registry entry for NCT00004026 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CTI BioPharma, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which chemotherapy is the first listed.
NCT00004026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004026 about?
NCT00004026 is a clinical study titled "CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. CT-2584 may stop the growth of prostate cancer by stopping blood flow to the tumor. PURPOSE: Randomized phase II trial to study the effectiveness of CT-2584 in treating patients w...
What is the current status of trial NCT00004026?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 1998-12. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00004026?
The interventions under investigation include: chemotherapy (DRUG), CT-2584 (DRUG).
Who is sponsoring clinical trial NCT00004026?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.